What this reading room is
Doctor Wolverine is an independent editorial project. It publishes summaries of the peer-reviewed research on two synthetic peptides — BPC-157 and TB-500 — that researchers and athletes have, for roughly a decade, co-administered under a single shorthand: the Wolverine blend. The name is research-community vernacular. It refers to a rapid-healing phenotype reported in rodent models and described in forum posts, nothing more. It has no relationship to any character or property held by Marvel Entertainment, Marvel Comics, or The Walt Disney Company.
The site sets out what the literature actually shows, where it is solid, and where it thins to the point of being almost entirely mechanistic extrapolation. Each page is set as a kind of typographic broadside: oversized lettering on a cream page, a quiet body of prose, and a marginal column of citations that can be hovered for the source. Nothing on this site is sold. Nothing is recommended. The reading room is open.
A typographic composition: a single oversized letterform in ink, registered against the paper by a single brick-red hairline.
The compounds, briefly
BPC-157 is a synthetic fifteen-amino-acid peptide with the sequence GEPPPGKPADDAGLV, modelled on a fragment of a cytoprotective protein originally isolated from human gastric juice in the early 1990s[1]. Across more than thirty years of preclinical work — much of it from the laboratory of Sikiric and colleagues at the University of Zagreb — BPC-157 has been studied in rats, mice, and dogs for tendon healing, muscle reattachment, intestinal anastomoses, spinal-cord and brain injury, and ischemia-reperfusion damage[1][2][3][4][20].
TB-500, as sold by research-chemical suppliers, is something narrower than vendor literature usually admits. It is a synthetic seven-amino-acid fragment, Ac-LKKTETQ-OH, corresponding to residues 17–23 of the full forty-three-amino-acid thymosin beta-4 (Tβ4)[22]. The fragment is the central actin-binding helix. It is not the whole molecule. Most of the human and clinical-grade preclinical efficacy data that vendors cite — the corneal program, the venous-stasis-ulcer trial, the cardiac repair work, the Phase I intravenous safety study — were generated with full-length Tβ4[9][10][11][12][13][14][22]. The site is explicit about this distinction wherever it matters.
The question of synergy
Both compounds touch tissue repair from different directions. BPC-157 acts at the injury site through angiogenic and cytoprotective signalling — most prominently a VEGFR2-PI3K-Akt-eNOS cascade — and through growth-hormone-receptor upregulation in tendon fibroblasts[2][4]. TB-500 / Tβ4 acts inside the cell, where its LKKTETQ helix binds monomeric G-actin in one-to-one stoichiometry and regulates the cytoskeletal dynamics that drive cell migration, including the mobilisation of progenitor populations toward injury[9][10][22].
The complementarity is the case for combining them. It is also, at this writing, the limit of the case. — Editorial summary, Doctor Wolverine
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine and a 2025 HSS Journal systematic review on BPC-157 both record that no controlled head-to-head or combination preclinical study of BPC-157 and TB-500 has been published in a peer-reviewed journal[6][7][25]. The synergy that vendors describe is an extrapolation. It may turn out to be real; it has not yet been demonstrated.
The regulatory record
In September 2023, the United States Food and Drug Administration placed both BPC-157 and TB-500 / thymosin beta-4 on its Category 2 list of bulk drug substances that may present significant safety risks under section 503A. That placement effectively excludes both from legal pharmacy compounding for human use in the United States[7].
The World Anti-Doping Agency lists BPC-157 under category S0 — non-approved substances, prohibited at all times — explicitly named on the 2022 list and on every annual list since. TB-500 / thymosin beta-4 is listed under category S2 — peptide hormones, growth factors and related substances — also prohibited at all times. A 2024 Canadian Centre for Ethics in Sport decision produced a four-year ineligibility for an athlete who used the two peptides together. Neither compound is approved by the European Medicines Agency for any indication. Neither is a controlled substance under the U.S. Controlled Substances Act.
How to read the rest of the site
The /research page is the long read. It sets out the mechanism in detail, walks through the major rodent studies, summarises the three small human BPC-157 reports, and treats the Tβ4 clinical record separately from the TB-500 fragment marketing record. The /dosage page is research-context only — what doses appear in the published literature, in which species, by which route — never a recommendation. The /faq answers the questions that recur on research-peptide forums and in laboratory inboxes. The /references page lists every source the site cites. The /about page describes the editorial standards and the disclaimer at the foot of every page is the contract: for research purposes only.